Skip to main content
Premium Trial:

Request an Annual Quote

Incyte and Genomic Health to Collaborate on Consumer Genomic Applications

NEW YORK, May 7 - Incyte has signed a collaboration with Palo Alto, Calif., startup  Genomic Health to develop consumer health applications for genomics, the companies said Monday.

Genomic Health is a privately-held applied genomics company founded by Incyte co-founder Randy Scott, Genentech scientists Joffre Baker and Steven Shak; organizational development expert Gene Early, and Patrick Terry, a health care consumer advocate. Incyte participated in the latest round of financing for this company.

Under the agreement, Genomic Health will have access to Incyte's LifeSeq Gold and BioKnowledge databases as well as other Incyte intellectual property. Incyte said Genomic Health would pay a similar fee to that paid by other licensees to its databases and information, although the parties did not disclose further financial terms of the agreement.

Other Investors in Genomic Health include Kleiner Perkins Caufield & Byers; Versant Ventures; Baker Tisch Investments, and CHL Medical Partners.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.